Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gains from Sales and Divestitures: 2014-2016

Historic Gains from Sales and Divestitures for Viridian Therapeutics, Inc.\DE (VRDN) over the last 2 years, with Dec 2016 value amounting to $52,668.

  • Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures fell 88.53% to $52,668 in Q4 2016 from the same period last year, while for Dec 2016 it was $52,668, marking a year-over-year decrease of 88.53%. This contributed to the annual value of $52,668 for FY2016, which is 88.53% down from last year.
  • Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures amounted to $52,668 in Q4 2016, which was down 65.87% from $154,308 recorded in Q3 2016.
  • Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures' 5-year high stood at $459,208 during Q4 2015, with a 5-year trough of $2,352 in Q1 2016.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Gains from Sales and Divestitures value was $154,308 (recorded in 2016), while the average stood at $200,390.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures soared by 61.19% in 2015, and later plummeted by 98.15% in 2016.
  • Quarterly analysis of 3 years shows Viridian Therapeutics, Inc.\DE's Gains from Sales and Divestitures stood at $284,893 in 2014, then spiked by 61.19% to $459,208 in 2015, then tumbled by 88.53% to $52,668 in 2016.
  • Its Gains from Sales and Divestitures was $52,668 in Q4 2016, compared to $154,308 in Q3 2016 and $128,956 in Q2 2016.